Research Summary In this randomized, controlled, Phase III study,1 patients with resectable, epidermal growth factor receptor (EGFR)–mutated, Stage II to IIIB non-small cell lung cancer (NSCLC) were assigned 1:1:1 to receive neoadjuvant osimertinib (80mg orally once daily for at least nine weeks) plus platinum-based chemotherapy...

Research Summary Concurrent chemoradiotherapy (cCRT) followed by adjuvant durvalumab is the standard first-line treatment for patients with unresectable Stage III non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) expression of one percent or higher. Although KRAS mutations are common in NSCLC, their prognostic...

Research Summary For patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), EGFR-tyrosine kinase inhibitors (TKIs) can be used as first-line treatment. However, treatment resistance often occurs with first- or second-generation EGFR-TKI treatment, with T790M mutation being the most common acquired resistance...

Research Summary Up to 35 percent of patients with completely resected non-small cell lung cancer (NSCLC) experience locoregional recurrence (LR), and many of these patients cannot undergo further surgery. Other treatment methods are thus necessary for this patient population. Patients with LR following complete resection...

Research Summary Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations have a notably increased incidence of brain metastases, compared to patients without EGFR mutations. Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor, has demonstrated intracranial activity, and an American Society of...